---
title: "Vascular Therapies completes enrolment in the ACCESS 2 study"
date: "2024-08-06T15:20:16.000Z"
publishedDate: "6 août 2024"
summary: "Vascular Therapies has today announced completion of enrolment in the ACCESS 2 trial, a Phase III prospective randomised, multicentre clinical study of Sirogen for the surgical creation of arteriovenous (AV) fistula in patients requiring haemodialysis vascular access. Vascular Therapies developed its sirolimus formulation (Sirogen) for intraoperative local, perivascular drug delivery."
importance: ""
sourceUrl: "https://vascularnews.com/vascular-therapies-completes-enrolment-in-the-access-2-study/"
tags: ["France", "Actualité", "Vascular News — Latest"]
permalink: "/papers/2024-08-06-vascular-therapies-completes-enrolment-in-the-access-2-study"
imageUrl: "https://vascularnews.com/wp-content/uploads/sites/7/2024/08/Vascular-Therapies-logo-web.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://vascularnews.com/vascular-therapies-completes-enrolment-in-the-access-2-study/"
---

![Vascular Therapies completes enrolment in the ACCESS 2 study](https://vascularnews.com/wp-content/uploads/sites/7/2024/08/Vascular-Therapies-logo-web.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://vascularnews.com/vascular-therapies-completes-enrolment-in-the-access-2-study/*

## L’essentiel

Vascular Therapies has today announced completion of enrolment in the ACCESS 2 trial, a Phase III prospective randomised, multicentre clinical study of Sirogen for the surgical creation of arteriovenous (AV) fistula in patients requiring haemodialysis vascular access. Vascular Therapies developed its sirolimus formulation (Sirogen) for intraoperative local, perivascular drug delivery.

## Lien source

https://vascularnews.com/vascular-therapies-completes-enrolment-in-the-access-2-study/
